| A seven-part series on the chances for immunizing the world against ...
As of May 2007, Congress had given the Department of Health and Human Services (HHS) $5.6 billion for pandemic preparedness; HHS has allocated $3.2 billion of that to expanding vaccine capacity. So far the agency has committed $1.5 billion of those funds, including $1 billion for research into alternative production methods such as cell culture, $147 million for research on low-dose vaccines, and $133 million for retrofitting existing plants to improve manufacturing capacity (see Bibliography: HHS 2007; Trust for America's Health 2007). "We are finally starting to do the right thing, because money is being put in," Poland said, "but we are late. We are really playing catch-up" (see Bibliography: Poland 2007). For the two years since federal money began flowing, scientific and public health groups have begged the administration to allocate more.
Grunt Work
It also has a well-constructed patch rollback "safety net" mechanism. You have to construct a local shared repository to keep copies of downloaded patches and the Reporting Center. A SQL Server database keeps system records and patch history information. I ran into a couple of small problems and anonymously (meaning they didn't know I reviewing the product) called tech support. More on that later, but whatever Ecora is paying them it isn't enough. Once everything is put together, EPM employs a Web licensing service after you install the application and run it for the first time. EPM automatically discovers, analyzes and deploys security patches critical to workstations and servers from your desktop and offers patch coverage for the most popular Microsoft products, including Windows NT/2000/2003/XP, Internet Explorer, Exchange, IIS, Media Player, Office, Outlook and SQL Sever.
Hercules Technology Provides $20 Million of Growth Capital to Israeli ...
Companies interested in learning more about financing opportunities should contact info@HTGC.com, or call 650.289.3060. About Kamada: Kamada is a public biopharmaceutical company (TASE:KMDA) developing, producing and marketing a line of specialty life-saving therapeutics using its proprietary chromatographic purification technologies. Licensed and marketed in more than 15 countries, several of these specialty therapeutics hold registered and pending patents and are currently in advanced clinical trials. For additional information, please visit www.kamada.com. Forward-Looking Statements: The statements contained in this release that are not purely historical are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties and other factors we identify from time to time in our filings with the Securities and Exchange Commission.
|
